[EN] SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS<br/>[FR] HYDANTOINAMIDES SUBSTITUÉS EN TANT QU'ANTAGONISTES D'ADAMTS7
申请人:BAYER AG
公开号:WO2021094434A1
公开(公告)日:2021-05-20
The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl; R2 is hydrogen or alkyl; A is 5-membered heteroaryl; Z is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; all groups being optionally substituted.
该申请涉及公式(I)的替代咪唑酰脲作为ADAMTS7拮抗剂,以及它们的制备方法,它们单独或与其他药物联合用于治疗或预防疾病,特别是心血管疾病,包括动脉粥样硬化、冠状动脉疾病(CAD)、外周血管疾病(PAD)、动脉闭塞病或血管成形术后再狭窄。R1为氢、烷基、环烷基、杂环烷基、5-至6-成员杂芳基或苯基;R2为氢或烷基;A为5-成员杂芳基;Z为6-至10-成员芳基或5-至10-成员杂芳基;所有基团均可选择性地被取代。